National Cancer Institute National Cancer Institute
U.S. National Institutes of Health National Cancer Institute
NCI Home Cancer Topics Clinical Trials Cancer Statistics Research & Funding News About NCI

Understanding Cancer Series: Molecular Diagnostics
< Back to Main
In English En español
    Posted: 01/28/2005    Reviewed: 09/01/2006
Page Options
Print This Page  Print This Page
Print This Document  Print This Document
View Entire Document  View Entire Document
E-Mail This Document  E-Mail This Document
PDF Version  View/Print PDF
PowerPoint Version  View/Print PowerPoint
Quick Links
Director's Corner

Dictionary of Cancer Terms

NCI Drug Dictionary

Funding Opportunities

NCI Publications

Advisory Boards and Groups

Science Serving People

Español
NCI Highlights
New Study of Targeted Therapies for Breast Cancer

The Nation's Investment in Cancer Research FY 2009

President's Cancer Panel Annual Report: 2006-2007

Cancer Trends Progress Report: 2007 Update

Past Highlights
HPV Vaccines for Cervical Cancer
Slide 33 : Importance of Diagnostic Test Sensitivity (cont.) previousnext

The first hurdle is a test's sensitivity. Sensitivity answers this question: What percentage of people with a given type of cancer will have their cancer detected when a given screening test is used? If a test is not very sensitive, there will be many "false negative" results, and persons with cancer will go undetected. A test that yields many false negatives will obviously not be very good at reducing cancer deaths, giving a false sense of security to people who actually have the disease.

Importance of Diagnostic Test Sensitivity (cont.)

< Previous  |  Index  |  Next Slide >


A Service of the National Cancer Institute
Department of Health and Human Services National Institutes of Health USA.gov